Mass Medical Angels
Isaiah Davis currently serves as a Director at Merck, starting in July 2024, and has been an Associate at Mass Medical Angels since July 2017, where responsibilities include liaising between Novartis and third-party medical technology providers and assisting with due diligence. Prior experience includes roles as Associate Director at Vertex Pharmaceuticals and Novartis Institutes for BioMedical Research (NIBR), where Isaiah Davis facilitated alliances and managed collaborations to advance research and development. Early career positions included Scientist I and Associate Scientist II at various prestigious institutions, contributing to efficiency and cost savings in laboratory operations. Isaiah Davis holds an MBA in Health Care Administration and Management from Boston University and a BS in Biology from Providence College.
This person is not in any teams
Mass Medical Angels
Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.